Covalon Technologies Ltd.

Covalon Technologies Ltd. researches, develops, manufactures, markets, and licenses medical technologies and products worldwide. The company has three proprietary platform technologies, including collagen matrix platform that is used to manufacture a family of products that treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; antimicrobial silicone adhesive platform, which is used in a family of pre-surgical, post surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone; and medical coating platform, a proprietary process that utilizes photo-polymerization to create active grafting sites where new polymer chains are initiated and propagated from the surface of an existing medical device. It sells wound care dressing, surgical and peri-operative, and infection management products under the Covalon brand name. The company offers its technologies, products, and services to various health care providers, such as hospitals, wound care centers, burn centers, extended/alternate care facilities, acute care facilities, home health care agencies, and physicians' offices. Covalon Technologies Ltd. is based in Mississauga, Canada.